UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported) – January 9, 2008

 

 

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

 

Pennsylvania

 

1-8036

 

23-1210010

(State or other jurisdiction

 

(Commission File Number)

 

(IRS Employer

of incorporation)

 

 

 

Identification No.)

 

 

 

 

 

101 Gordon Drive, PO Box 645,

 

 

Lionville, PA

 

19341-0645

(Address of principal executive offices)

 

(Zip Code)

 

610-594-3319

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 


 

Item 7.01 Regulation FD Disclosure

 

West Pharmaceutical Services, Inc. (the “Company”) will make a presentation at the CJS Securities 8th Annual “New Ideas for the New Year” Investor Conference at the St. Regis Hotel in New York City on Wednesday, January 9, 2008.

 

A copy of the Company’s presentation from the conference will be available for 30 days through the Investor link at the Company’s website, http://www.westpharma.com., and is also attached hereto as Exhibit 99.1. The Exhibit is incorporated herein by reference.

 

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 9.01 Financials Statement and Exhibits

 

(d)

Exhibits

 

 

 

 

 

 

 

Exhibit #

 

Description

 

99.1

 

West Pharmaceutical Services, Inc. Corporate Overview (Investor Presentation).

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 WEST PHARMACEUTICAL SERVICES, INC.

 

 

 

 /s/ John R. Gailey III

 

 

 John R. Gailey III

 

 Vice President, General Counsel and Secretary

 

 

January 9, 2008

 

3